2-oxo-N-phenylindoline-5-carboxamide | 1168720-81-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-oxo-N-phenylindoline-5-carboxamide
• 英文别名: 2-oxo-N-phenyl-1,3-dihydroindole-5-carboxamide
• CAS: 1168720-81-7
• 化学式: C₁₅H₁₂N₂O₂
• 分子量: 252.272
• InChiKey: BRXOMFVOSKBYJS-UHFFFAOYSA-N

物化性质

• 沸点：
  419.9±45.0 °C(predicted)
• 密度：
  1.328±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1H-吲唑-6-甲醛 、 2-oxo-N-phenylindoline-5-carboxamide 在 哌啶 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以24%的产率得到(E)-3-((1H-indazol-6-yl)methylene)-2-oxo-N-phenylindoline-5-carboxamide
  参考文献：
  名称：

  [EN] INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  [FR] DÉRIVÉS D'INDOLMONE À SUBSTITUTION INDAZOLYLE, BENZIMIDAZOLYLE, BENZOTRIAZOLYLE EN TANT QU'INHIBITEURS DE KINASES UTILISÉS DANS LE TRAITEMENT DU CANCER

  摘要：

  公开号：

  WO2009079767A9
• 作为产物：
  描述：

  对氨基苯甲酸 在 盐酸 、 hydrazine hydrate 、 硫酸 、 盐酸羟胺 、 sodium sulfate 、 O‐(1H‐benzotriazol‐1‐yl)‐N,N,N′,N′‐tetramethyluronium tetrafluoroborate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 2-oxo-N-phenylindoline-5-carboxamide
  参考文献：
  名称：

  Synthesis, anti-lung cancer activity and molecular docking study of 3-methylene-2-oxoindoline-5-carboxamide derivatives

  摘要：

  A series of 3-methylene-2-oxoindoline-5-carboxamide derivatives were synthesized in appreciable yield by using 4-aminobenzoic acid as a starting material. The preliminary biological test results showed that most compounds displayed potent inhibitory activity against proliferation of human lung adenocarcinoma epithelial cell line (A549) in MTT assay. Compound 6l displayed the highest potency (IC50 = 3.0 mu M). The western blot analysis demonstrated a correlation between anti-proliferative activity of active compounds and blockade of the phosphorylation of extracellular signal-regulated kinases (ERK1/2). The docking study also provides new insights into further optimization of 3-methylene-2-oxoindoline-5-carboxamide derivatives for the discovery of more potent RAF/MEK/ERK pathway regulators as anti-lung cancer agents.

  DOI：

  10.1007/s00044-017-2050-3

文献信息

• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：Pauls Heinz W.

  公开号：US20110065702A1

  公开（公告）日：2011-03-17

  The present invention is directed to a compound is represented by Structural Formula (A):or a pharmaceutically acceptable salt therof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，其结构式表示为(A)或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式(A)所表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗患有癌症的受试者的方法，其中该方法包括给予上述结构式(A)所表示的化合物或其药学上可接受的盐的治疗有效量。
• Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
  申请人：Pauls Heinz W.

  公开号：US08765748B2

  公开（公告）日：2014-07-01

  The present invention is directed to a compound is represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The present invention is also directed to a pharmaceutical composition comprising a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent. Also disclosed is a method of treating a subject having cancer, wherein the method comprises administering a therapeutically effective amount of a compound represented by Structural Formula (A) described above or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由结构式（A）表示的化合物或其药学上可接受的盐。本发明还涉及一种药物组合物，包括上述结构式（A）表示的化合物或其药学上可接受的盐，以及药学上可接受的载体或稀释剂。本发明还揭示了一种治疗癌症患者的方法，其中该方法包括给予上述结构式（A）表示的化合物或其药学上可接受的盐的治疗有效量。
• Design and synthesis of indol-2-one derivatives as potential RET inhibitors
  作者：Zhenzhu Li、Kai Sun、Yuanhong Xu、Fuli Zhu、Zhenyu Mao、Yang Wang、Yaxia Yuan、Ting Qiu、Xiabin Chen、Lei Ma

  DOI：10.1016/j.bmcl.2023.129538

  日期：2024.1

  We synthesized and assessed five series of indol-2-one derivatives for their potential as RET kinase inhibitors. Notably, compounds B3, B6, D1, D2, D3, and D5 demonstrated significant inhibitory activity. Among these, D5 exhibited the best activity of inhibiting RET kinase, which provided reference for the subsequent development of RET kinase inhibitors as anti-thyroid cancer chemical.

  我们合成并评估了五个系列的吲哚-2-酮衍生物作为 RET 激酶抑制剂的潜力。值得注意的是，化合物 B3 、 B6 、 D1 、 D2 、 D3 和 D5 表现出显著的抑制活性。其中，D5 对 RET 激酶的抑制活性最好，为后续开发 RET 激酶抑制剂作为抗甲状腺癌化学物质提供了参考。
• INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER
  申请人：University Health Network

  公开号：EP2235004A1

  公开（公告）日：2010-10-06
• US8765748B2
  申请人：——

  公开号：US8765748B2

  公开（公告）日：2014-07-01